CY1105235T1 - Συνθεσεις λασοφοξιφενης - Google Patents

Συνθεσεις λασοφοξιφενης

Info

Publication number
CY1105235T1
CY1105235T1 CY20061101350T CY061101350T CY1105235T1 CY 1105235 T1 CY1105235 T1 CY 1105235T1 CY 20061101350 T CY20061101350 T CY 20061101350T CY 061101350 T CY061101350 T CY 061101350T CY 1105235 T1 CY1105235 T1 CY 1105235T1
Authority
CY
Cyprus
Prior art keywords
lasofoxifene
compositions
achieve
effect
potency
Prior art date
Application number
CY20061101350T
Other languages
English (en)
Inventor
David Duane Thompson
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of CY1105235T1 publication Critical patent/CY1105235T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Με βάση την ημιζωή και τη δραστικότητα της λασοφοξιφένης, το φάρμακο μπορεί να χορηγείται μία φορά την εβδομάδα και να επιτυγχάνει ένα παρόμοιο αποτέλεσμα ως εάν χορηγούνταν ημερησίως. Αναλόγως, η εφεύρεση αναφέρεται σε νέες συνθέσεις λασοφοξιφένης και στην παρασκευή τους οι οποίες επιτυγχάνουν αυτό το αποτέλεσμα.
CY20061101350T 1999-09-29 2006-09-20 Συνθεσεις λασοφοξιφενης CY1105235T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15665299P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
CY1105235T1 true CY1105235T1 (el) 2010-03-03

Family

ID=22560457

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101350T CY1105235T1 (el) 1999-09-29 2006-09-20 Συνθεσεις λασοφοξιφενης

Country Status (20)

Country Link
US (1) US6436977B1 (el)
EP (1) EP1092431B1 (el)
JP (1) JP2001097862A (el)
KR (1) KR100468246B1 (el)
AT (1) ATE339201T1 (el)
AU (1) AU781828B2 (el)
CA (1) CA2321369C (el)
CO (1) CO5200833A1 (el)
CY (1) CY1105235T1 (el)
DE (1) DE60030654T2 (el)
DK (1) DK1092431T3 (el)
ES (1) ES2269071T3 (el)
HU (1) HUP0003836A3 (el)
IL (1) IL138634A (el)
MY (1) MY121519A (el)
NZ (2) NZ507200A (el)
PE (1) PE20010680A1 (el)
PT (1) PT1092431E (el)
TW (1) TWI224001B (el)
ZA (1) ZA200005141B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
WO2003004032A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
NZ752443A (en) 2016-10-11 2022-11-25 Univ Duke Lasofoxifene treatment of er+ breast cancer
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (en) 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications

Also Published As

Publication number Publication date
EP1092431A2 (en) 2001-04-18
NZ507200A (en) 2004-12-24
EP1092431A3 (en) 2002-02-13
EP1092431B1 (en) 2006-09-13
KR100468246B1 (ko) 2005-01-27
AU781828B2 (en) 2005-06-16
KR20010061927A (ko) 2001-07-07
JP2001097862A (ja) 2001-04-10
CA2321369A1 (en) 2001-03-29
DK1092431T3 (da) 2006-12-18
DE60030654T2 (de) 2007-04-05
IL138634A (en) 2006-08-01
US6436977B1 (en) 2002-08-20
NZ516413A (en) 2004-12-24
HU0003836D0 (en) 2000-12-28
HUP0003836A2 (hu) 2001-10-28
ATE339201T1 (de) 2006-10-15
CA2321369C (en) 2007-07-17
MY121519A (en) 2006-01-28
PE20010680A1 (es) 2001-06-29
TWI224001B (en) 2004-11-21
ES2269071T3 (es) 2007-04-01
AU5661800A (en) 2001-04-05
HUP0003836A3 (en) 2002-09-30
DE60030654D1 (de) 2006-10-26
ZA200005141B (en) 2002-03-26
IL138634A0 (en) 2001-10-31
CO5200833A1 (es) 2002-09-27
PT1092431E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
CY1110351T1 (el) Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση
PT1109812E (pt) Pirrolobenzodiazepinas
EA199900373A2 (ru) Фармацевтические композиции
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
CY1107951T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY1108559T1 (el) Αλατα βαλσαρτανης
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
NO20024891D0 (no) Farmasöytiske sammensetninger
DK0994710T3 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
BR0210139A (pt) Composições farmacêuticas
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
HUP9903931A2 (hu) Indolopirrolokarbazolok citotoxikus aminocukor- és más rokon jellegű cukorszármazékai
NO974321D0 (no) Nodulisporsyrederivater
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c